Evidence map›Paper›PMID 39456602›Full record

ArticleCancers2024

Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database.

David E Kaplan, Ruoding Tan, Cheryl Xiang, Fan Mu, Sairy Hernandez, Sarika Ogale, Jiayang Li, Yilu Lin, Lizheng Shi, Amit G Singal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

David E KaplanDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-3839-336X
Ruoding TanGenentech, South San Francisco, CA 94080, USA.
Cheryl XiangAnalysis Group Inc., Boston, MA 02199, USA.
Fan MuAnalysis Group Inc., Boston, MA 02199, USA.
Sairy HernandezGenentech, South San Francisco, CA 94080, USA.
Sarika OgaleGenentech, South San Francisco, CA 94080, USA.
Jiayang LiAnalysis Group Inc., Boston, MA 02199, USA.
Yilu LinDepartment of Health Policy and Management, Tulane University, New Orleans, LA 70118, USA.ORCID 0000-0001-7040-4287
Lizheng ShiDepartment of Health Policy and Management, Tulane University, New Orleans, LA 70118, USA.ORCID 0000-0002-7827-6766
Amit G SingalDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

Funding

Genentech N/A
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

atezolizumabbevacizumabhepatocellular carcinomalenvatinibNational Veterans Health Administration databaseoverall survivalreal worldsorafenib

Identifiers

PMID39456602
PMCPMC11506031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.